Otsuka And Lundbeck Submit SNDA For FDA Review Of Brexpiprazole And Sertraline Combination As Potential Treatment For Ptsd
09/04/2024 07:02
April 9 (Reuters) - Otsuka Holdings Co Ltd 4578.T :
* OTSUKA HOLDINGS CO LTD: OTSUKA AND LUNDBECK SUBMIT SNDA
FOR FDA
REVIEW OF BREXPIPRAZOLE AND SERTRALINE COMBINATION AS POTENTIAL
TREATMENT FOR PTSD
Source text for Eikon: ID:nTSpi8a94e
Further company coverage: 4578.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug